2-(4-氯-3-硝基苯基磺酰胺基)苯甲酸
2-(4-氯-3-硝基苯基磺酰胺基)苯甲酸 性质
| 沸点 | 564.8±60.0 °C(Predicted) |
|---|---|
| 密度 | 1.660±0.06 g/cm3(Predicted) |
| 储存条件 | Store at -20°C |
| 溶解度 | 二甲基亚砜：125mg/mL（350.40mM） |
| 形态 | 固体 |
| 酸度系数(pKa) | 3.19±0.36(Predicted) |
| 颜色 | 米白色至浅黄色 |
| EPA化学物质信息 | Benzoic acid, 2-[[(4-chloro-3-nitrophenyl)sulfonyl]amino]- (68003-38-3) |
2-(4-氯-3-硝基苯基磺酰胺基)苯甲酸 用途与合成方法
| Target | Value |
|
glycolysis
() | |
|
SLC25A1
(Cell-free assay) | 3.5 μM(Kd) |
CTPI-2 is a unique regulator of glycolysis that limits the metabolic plasticity of cancer stem cells (CSCs). CTPI-2 (26 mg/kg; i.p.) inhibits tumor growth in in vivo models of non-small cell lung cancer (NSCLC).
CTPI-2 (50 mg/kg; i.p.; alternate days for 12 weeks) completely averts weight gain in the prevention study and leads to significant weight loss in the reversion study.
CTPI-2 prevents steatohepatitis and normalizes glucose tolerance. CTPI-2 lowers the levels of circulating IL-6 while increasing anti-inflammatory IL-4 and IL-10 and also reduced the monocyte chemoattractant protein-1 and monokine-induced by interferon-γ that attract neutrophils and monocytes. CTPI-2 regulates the citrate pool, the lipogenic and the gluconeogenic pathways.
| Animal Model: | C57BL/6J mice (HFD-fed mice) |
| Dosage: | 50 mg/kg |
| Administration: | Alternate days via the intraperitoneal route for 12 weeks |
| Result: | Completely averted weight gain in the prevention study and led to significant weight loss in the reversion study. |
2-(4-氯-3-硝基苯基磺酰胺基)苯甲酸 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-04-30 | S2968 | 2-(4-氯-3-硝基苯基磺酰胺基)苯甲酸 | 68003-38-3 | 5mg | 1384.11 |
| 2024-04-30 | S2968 | 68003-38-3 | 10mM (1mL in DMSO) | 1613.43 |
